OncoKB New Data Release - November 26, 2024
Contact OncoKB
Data Release v4.23
November 26, 2024
What's New
Updated Therapeutic Implications:
New alteration(s) with a tumor type-specific level of evidence
Level 1: KMT2A Fusions in mixed phenotype acute leukemia based on FDA approval of Revumenib in adult and pediatric patients 1 year and older with relapsed or refractory acute leukemia with a KMT2A translocation (PMID: 39121437)
Addition of sensitivity-associated therapy(s) for an alteration(s) with a tumor type-specific resistance level of evidence
Level 4: Addition of Zurletrectinib to NTRK1 G595R in all solid tumors based on preclinical data of NTRK1 G595R-mutant cell lines and xenograft models demonstrating sensitivity to zurletrectinib (PMID: 38902532)
Resistance-associated evidence currently in OncoKB™ for NTRK1 G595R (Level R1 in all solid tumors - Larotrectinib)
Level 3A: Addition of Selitrectinib to NTRK3 G623R in all solid tumors based on based on clinical responses to selitrectinib in patients with NTRK3 fusion-positive solid tumors expressing NTRK3 G623R, and accompanying preclinical data (PMID: 32133433, 33004339, 28578312, 34625502)
Level 4: Addition of Zurletrectinib to NTRK3 G623R in all solid tumors based on based on preclinical data of NTRK3 G623R-mutant cell lines and xenograft models demonstrating sensitivity to zurletrectinib (PMID: 38902532)
Resistance-associated evidence currently in OncoKB™ for NTRK3 G623R (Level R1 in all solid tumors - Larotrectinib)
Promotion of tumor type-specific level of evidence for an alteration
Level 1: KMT2A Fusions in acute myeloid leukemia and B-cell lymphoblastic leukemia/lymphoma promoted from Level 3A to Level 1 based on FDA approval of Revumenib in adult and pediatric patients 1 year and older with relapsed or refractory acute leukemia with a KMT2A translocation (PMID: 39121437)
Addition of drug(s) associated with a tumor type-specific leveled alteration(s) currently in OncoKB™ (without changing the alteration's highest level of evidence)
Level 4: Addition of Zurletrectinib to NTRK1/2/3 Fusions in all solid tumors based on preclinical data of NTRK fusion positive-cell lines and xenograft models demonstrating sensitivity to zurletrectinib (PMID: 38902532)
Sensitivity-associated evidence currently in OncoKB™ for NTRK1/2/3 Fusions (Level 1 in non-small cell lung cancer- Entrectinib, Larotrectinib, Repotrectinib)
Removal of therapy(s) associated with a tumor type-specific leveled alteration(s) (without changing the alteration's highest level of evidence)
Level 4: Removal of LOXO-783, LOXO-783 + Aromatase Inhibition Therapy + Abemaciclib, LOXO-783 + Fulvestrant, LOXO-783 + Fulvestrant + Abemaciclib, LOXO-783 + LY3484356, LOXO-783 + LY3484356 + Abemaciclib and LOXO-783 + Paclitaxel from PIK3CA H1047R in all solid tumors based on discontinuation of LOXO-783 development
Sensitivity-associated evidence currently in OncoKB™ for PIK3CA H1047R (Level 4 in all solid tumors - RLY-2608, RLY-2608 + Fulvestrant)
Gene Curation:
Addition of 6 new genes:
We're Here to Help
As always, don’t hesitate to reach out if you have comments, questions or suggestions. We love to hear from you. You can reach us at con...@oncokb.org
